Antitumor activity of Z-endoxifen in aromatase inhibitor-sensitive and aromatase inhibitor-resistant estrogen receptor-positive breast cancer

BACKGROUND: The tamoxifen metabolite, Z-endoxifen, demonstrated promising antitumor activity in endocrine-resistant estrogen receptor-positive (ER+) breast cancer. We compared the antitumor activity of Z-endoxifen with tamoxifen and letrozole in the letrozole-sensitive MCF7 aromatase expressing mode...

Descripción completa

Detalles Bibliográficos
Autores principales: Jayaraman, Swaathi, Hou, Xiaonan, Kuffel, Mary J., Suman, Vera J., Hoskin, Tanya L., Reinicke, Kathryn E., Monroe, David G., Kalari, Krishna R., Tang, Xiaojia, Zeldenrust, Megan A., Cheng, Jingfei, Bruinsma, Elizabeth S., Buhrow, Sarah A., McGovern, Renee M., Safgren, Stephanie L., Walden, Chad A., Carter, Jodi M., Reid, Joel M., Ingle, James N., Ames, Matthew M., Hawse, John R., Goetz, Matthew P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7238733/
https://www.ncbi.nlm.nih.gov/pubmed/32430040
http://dx.doi.org/10.1186/s13058-020-01286-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7238733/
https://www.ncbi.nlm.nih.gov/pubmed/32430040
http://dx.doi.org/10.1186/s13058-020-01286-7

Ejemplares similares